Cancer Vaccines
Tumor-associated antigens (TAA) are typically poorly immunogenic ‘self’ antigens. One strategy to break tolerance and induce immunity involves genetic vaccination employing homologous TAA sequences from a different species. In proof-of-concept studies, Mirus Bio has demonstrated that Pathway IV ™ delivery of plasmid DNA encoding tumor antigens can:
- Generate a robust humoral response
- Promote expansion of antigen-specific CD8+ T cells
- Induce cytolytic T-lymphocyte (CTL) activity
- Induce an effective anti-tumor response
We have previously shown that Pathway IV ™ delivery is equally effective in small and large animals for delivery and expression of plasmid DNA in limb myofibers, including mice, rats, dogs and monkey.
Together, these capabilities suggest that Pathway IV ™ may be a clinically effective platform through which to induce anti-tumor immunity. Mirus Bio is interested in collaborating with third parties to develop genetic cancer vaccines, combining Pathway IV ™ with the collaborator’s proprietary antigens. Please contact us for more information.
© 2008 Mirus Bio Corporation. All Rights Reserved.